Newsroom

Newsroom

News
Events

Featured

Alvotech enrolls first patient in clinical phase III study

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®

Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA^® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors

Read More

Alvotech enrolls first patient in clinical phase III study

Work begins on Alvotech-CCHN joint venture in China

Alvotech completes U.S. $300m financing deal

Fuji Pharma invests in Alvotech for US$50 million

Alvotech and Fuji Pharma enter into exclusive agreement

Alvotech and Changchun High & New Technology Industries enter into agreement

Alvotech receives manufacturing license for its biopharmaceutical facility

The race goes on

Rasmus Rojkjaer appointed CEO of Alvotech

Alvotech scores in Barcelona

Generics bulletin casts spotlight on Alvotech

Alvotech opens state-of-the-art biosimilar facility in Iceland

Acquisition of Baliopharm

Richard Davies new Chairman of the Board of Directors

Alvotech warming up for CPhI 2015 in Madrid

Alvotech recruits 40 professionals

Alvotech appoints Dr. Jennifer Hunt as Vice President of Operations

Alvotech opens 50 new positions

Alvotech scores high at CPhI in Paris

Alvotech warming up for CPhI

Alvotech and Finesse collaborate

Job openings at Alvotech

Alvotech invests $250 million in biopharmaceuticals

MEET THE MANAGEMENT

Highly experienced management team with a proven track record of achieving high...

Media Gallery

Download center for company logos and images.

News alert

Enter your email to sign up for news alerts

MEDIA CONTACT

Halldor Kristmannsson
Vice President
Organizational Development
Global Communications & Branding

Phone (354) 522-2900

Email
Connect on LinkedIn

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.